A team of Swedish researchers has received $3.3 million to develop a new nanotechnology platform for detecting blood-borne markers in lung and breast cancer.
QuantuMDx will use Scienion's ultra-low-volume liquid handling technologies in its Q-Poc handheld molecular diagnostic device.
The team showed the approach could successfully monitor cytokines in infants after heart surgery, and is involved now in a larger clinical study expanding this research.
Cambridge Bioscience will be NanoInk's exclusive distributor in the UK and Ireland, NanoInk said this week.
NanoInk has tapped two distributors to sell its nanofabrication platforms in the Asia Pacific region.
Avantra Biosciences' Rapid Assay Prototyping Service, NanoInk's NanoArray Assay System
Roughly 40 percent of the funding will go toward NanoInk's BioDiscovery division, where it will be used to build out the company's sales and marketing organization and fund development of new products based on its protein nanoarray platform.
In Nucleic Acids Research this week: nanopore sequencing workflow to detect antibiotic resistance in gut microbes, TSSPlant tool, and more.
Because gene-edited organisms can cross borders, Gizmodo wonders whether there should be an international body to govern their use.
HHS Secretary nominee Tom Price is to go in front of the Senate Committee on Health, Education, Labor and Pensions today, NPR's Morning Edition reports.
Prior to being closed, Theranos' Arizona lab failed an inspection by regulators, according to the Wall Street Journal.